Form D industry group

Pharmaceuticals

Rounds

2

Latest round

Series A 2026-02-24

Latest round amount

$197M

Total disclosed raised

$197Mderivedsum of disclosed round sizes only

Investors

4

People

1

Incorporated

2023

Revenue range

Decline to Discloseas stated on Form D

• Occurred

  Feb 24, 2026
  Round announced

  Alveus Therapeutics announced Series A of $197,000,000

  News and newswireobserved 6 days ago
  $197M
• Occurred

  Jan 14, 2026
  Form D filed

  Alveus Therapeutics, Inc. filed Form D: $56,862,480 sold of $110,724,980, Pharmaceuticals

  Form Dobserved 6 days ago
  $56.9M

Also named here, with no published line of their own (reach them through the firm): RAJ Kannan (Executive Officer/Director), Carlo de Notaristefani (Director), Claudio Nessi (Director), Gregory Parekh (Director), Garrett Ingram (Director), Ameet Nathwani (Director), Ivan Gergel (Director), JAN van de Bossche (Director).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Graph

Venture Capital

Canonical id

dfx:vc:9ca7063d-ace7-4ae6-b40e-843a3e9a7b0e

First observed

Sep 12, 2026

Last observed

Sep 14, 2026 4 days ago

Resolution

Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.